Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: BDR who wrote (6458)	5/4/1999 8:01:00 PM
From: Linda Kaplan	Read Replies (1) \| Respond to of 7041

Here's some long term data on Viagra's efficacy on a huge population: Headline: Erectile Dysfunction Patients Remain Satisfied With Viagra After Two Years, New Study Shows ====================================================================== Long-term Analysis Demonstrates Consistency With Safety Experience in Clinical Trials DALLAS, May 4 /PRNewswire/ -- An overwhelming majority of patients taking Pfizer Inc's (NYSE:PFE) Viagra (sildenafil citrate) said they remained satisfied with the erectile dysfunction medication after two years, according to data presented here today at the annual meeting of the American Urological Association. In a two-year study involving 401 patients, participants were asked every three months whether they were satisfied with the effect Viagra had on their erections. After two years of treatment, 93 percent of patients taking Viagra reported they remained satisfied with the medicine. The average age of the men who participated in the study was 55, and each had suffered from ED for an average of 4.5 years. Further, 16 percent of patients in the study also suffered from hypertension, 8 percent suffered from depression, 5 percent were diagnosed with ischemic heart disease and 4 percent had diabetes. Patients took either 25 mg, 50 mg or 100 mg of Viagra about an hour before sexual activity. The most common treatment-related side effects were flushing, headache and nasal congestion. Separately, data from the longest-term safety analysis of Viagra showed that Viagra remained a safe and well-tolerated treatment option for men with ED. The incidence of all myocardial infarctions -- or heart attacks -- was tracked in more than 6,500 patients who participated in 43 placebo-controlled clinical trials. The incidence of myocardial infarction was O.84 per 100 patient years for men receiving Viagra and 1.05 per 100 patient years among those receiving placebo. There is no statistically significant difference between these figures. "These data reaffirm the safety profile of Viagra and demonstrate how well it is accepted by men who suffer from this common and distressing condition," said Dr. Mike Sweeney, Medical Director for Viagra. "These new data are consistent with the data Pfizer presented to regulatory authorities in both the United States and Europe to secure Viagra's approval last year." Viagra is contraindicated in patients who use nitrates in any form, at any time, and should always be used in accord with the FDA-approved labeling. Viagra has been shown to result in small, transient decreases in blood pressure. ED is a serious medical condition that affects an estimated 30 million American men and their partners. It is frequently linked to serious underlying conditions such as depression, hypertension, diabetes and other cardiovascular diseases. Since its approval by the U.S. Food and Drug Administration on March 27, 1998, more than nine million Viagra prescriptions have been written in the United States alone, and the medicine has been taken by more than 4.5 million American patients. Viagra currently is available in more than 60 countries. The Pfizer-sponsored study was headed by Dr. Geoff Hackett of St. Chads Health Centre in Lichfield, Staffordshire, and Dr. Clive Gingell of Southmead Hospital in Westbury on Trym, Bristol, both in the United Kingdom. Pfizer Inc is a research-based global pharmaceutical company that discovers, develops, manufactures and markets innovative medicines for humans and animals. The company reported revenues of more than $13.5 billion in 1998 and expects to spend about $2.8 billion on research and development this year. In 1999, Pfizer celebrates its 150th anniversary. SOURCE Pfizer Inc -0- 05/04/99 /CONTACT: Mariann Caprino, 917-741-8026, or Andy McCormick, 212-573-1226, both of Pfizer Inc/ /Company News On-Call: Pfizer's press releases are available at no charge through PR Newswire's Company News On-Call fax service and on PRN's Web Site. For a menu of Pfizer press releases or to retrieve a specific release, call 800-758-5804, extension 688250, or prnewswire.com on the Internet./ /Photo: A free corporate logo to accompany this story is available immediately via Wieck Photo Database to any media with telephoto receiver or electronic darkroom, PC or Macintosh, that can accept overhead transmissions. To retrieve a logo, please call 972-392-0888./ /Company News On-Call: prnewswire.com or fax, 800-758-5804, ext. 688250/ /Web site: pfizer.com

To: BDR who wrote (6458)	5/5/1999 12:18:00 AM
From: Bruce Rosen	Read Replies (2) \| Respond to of 7041

<< Obtaining clearance to sell Vasomax in Mexico did require the expenditure of some resources (maybe not much, I don't know what is involved in the process in Mexico). After expending those resources there were no sales recognized. There are various reasons why that might be the case>> "There are various reasons why that might be the case." Good! We finally agree. My main point has been that none of us know what Schering's plan is. Therefore, no conclusions can be drawn from Mexico or, for that matter, Schering's decision not to participate in the AUA conference. Secrecy is a common practice in the competitive world of business. It should not be surprising that Schering would look for every edge. Remember, Vasomax does not need to "blow Viagra off the sales charts." A ten percent market share would make it a very successful drug. A thirty percent share would make it a blockbuster, especially for little Zonagen with less than 13 million shares outstanding, fully diluted. That is what makes this such a dangerous stock to short. <<Do you post to or follow any threads besides the ZONA thread?>> I peruse other threads, Dale, but I rely on you to post links to what I write, so there is no need for me to post elsewhere. I don't mean to torture you though. ;) Message 9302299 And you didn't think I have a sense of humor! Good luck, Bruce